IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

Arun has over 15 years’ experience covering the Technology sector. During this time, he has worked with technology start-ups and as an equity analyst in investment banks and independent research firms. He was formerly a Technology Analyst for Canaccord Genuity, Altium Securities, Espirito Santo Investment Bank, Noble Group and Clear Capital. He has a dual Master’s degree in Financial Engineering and Industrial and Operations Engineering from the University of Michigan. He obtained his Bachelor’s degree in Mechanical Engineering from the Indian Institute of Technology, Bombay. He is also a CFA charterholder.

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<div><p><a href="https://www.smartkarma.com/entities/wuxi-apptec" target="_blank" data-smartkarma-citation="entities:23679:1" rel="noopener">Wuxi Biologics (Cayman) Inc (2269 HK)</a> is a global one-stop biologics services provider and often referred to as CRO (contract research organisation) and/or CMO/CDMO (contract development and manufacturing organisation).</p></div><div><div><div class="content-highlight"><p>Wuxi Biologics has announced a primary and secondary placing.  The primary placing will raise net proceeds of HK$3,929 million ($504 million). We continue to believe that WuXi Biologics has strong fundamentals and the current share price provides a sufficient upside to warrant participating in the placing.</p></div></div></div>

Wuxi Biologics (Cayman) Inc (2269 HK) is a global one-stop biologics services provider and often referred to as CRO (contract research organisation) and/or CMO/CDMO (contract development and manufacturing organisation).Wuxi Biologics has announced a primary and secondary placing.  The primary placing will raise net proceeds of HK$3,929 million ($504 million). We continue to believe that WuXi Biologics has strong fundamentals and the current share price provides a sufficient upside to warrant participating in the placing.

WuXi Biologics Placement: An Attractive Opportunity